Robust Appetite For Biosolution IPO As OA Cell Therapy Nears Commercialization
Executive Summary
Biosolution's IPO, which was priced at the high end of the range despite dampened biotech sentiment following the arrest of Nature Cell's CEO, is poised to help accelerate commercialization of the South Korean cell therapy company's osteoarthritis treatment CartiLife and the progress of other pipeline assets.
You may also be interested in...
Nature Cell Mired In Uncertainty as CEO Arrested For Alleged Stock Price Manipulation
The Korean biotech’s CEO and several other executives’ alleged involvement in stock price manipulation using false and exaggerated information on a pipeline stem cell therapy has damaged the credibility of its R&D efforts and shocked the domestic industry, although their fate remains to be determined after court trials.
First Approval For Kolon's Invossa But No Disease-Modifying Status
Kolon Life Science's Invossa gets regulatory approval in South Korea as the world's first allogeneic cell-mediated gene therapy for degenerative osteoarthritis, but misses out on disease-modifying status, although the company hopes a large-scale Phase III study can rectify this in the US.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.